Indaptus Therapeutics, Inc. Operating Expenses
Indaptus Therapeutics, Inc. (INDP) reported Operating Expenses of $1.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Indaptus Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $1.81M, a 59.41% decline year-over-year.
- Indaptus Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $2.16M, a 52.77% decline year-over-year.
- Indaptus Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $8.16M, a 95.51% increase year-over-year.
- Indaptus Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $2.65M, a 15.71% decline year-over-year.
- Indaptus Therapeutics, Inc. operating expenses for fiscal 2025 was $19.83M, a 29.08% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. operating expenses for fiscal 2024 was $15.37M, a 6.18% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. operating expenses for fiscal 2023 was $16.38M, a 9.84% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. operating expenses for fiscal 2022 was $14.91M, a 92.92% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.81M 10-Q · filed 2026-08-13 | $3.97M 10-Q · filed 2026-08-13 | $12.12M derived: sum of 3 quarters · filed 2026-08-13 | $14.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.16M 10-Q · filed 2026-05-15 | $10.32M derived: sum of 2 quarters · filed 2026-05-15 | $12.96M derived: sum of 3 quarters · filed 2026-05-15 | $17.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $10.80M derived: sum of 2 quarters · filed 2026-03-17 | $15.26M derived: sum of 3 quarters · filed 2026-08-13 | $19.83M 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.65M 10-Q · filed 2025-11-12 | $7.11M derived: sum of 2 quarters · filed 2026-08-13 | $11.68M 10-Q · filed 2025-11-12 | $15.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.46M 10-Q · filed 2026-08-13 | $9.03M 10-Q · filed 2026-08-13 | $13.20M derived: sum of 3 quarters · filed 2026-08-13 | $16.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $4.57M 10-Q · filed 2026-05-15 | $8.74M derived: sum of 2 quarters · filed 2026-05-15 | $11.89M derived: sum of 3 quarters · filed 2026-05-15 | $16.00M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $7.31M derived: sum of 2 quarters · filed 2026-03-17 | $11.42M derived: sum of 3 quarters · filed 2026-03-17 | $15.37M 10-K · filed 2026-03-17 |
| 2024-09-30 | $3.14M 10-Q · filed 2025-11-12 | $7.25M derived: sum of 2 quarters · filed 2025-11-12 | $11.19M 10-Q · filed 2025-11-12 | $15.37M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.11M 10-Q · filed 2025-08-13 | $8.05M 10-Q · filed 2025-08-13 | $12.23M derived: sum of 3 quarters · filed 2025-08-13 | $16.48M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $3.94M 10-Q · filed 2025-05-14 | $8.12M derived: sum of 2 quarters · filed 2025-05-14 | $12.37M derived: sum of 3 quarters · filed 2025-05-14 | $15.87M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $8.43M derived: sum of 2 quarters · filed 2025-03-13 | $11.92M derived: sum of 3 quarters · filed 2025-03-13 | $16.38M 10-K · filed 2025-03-13 |
| 2023-09-30 | $4.25M 10-Q · filed 2024-11-12 | $7.74M derived: sum of 2 quarters · filed 2024-11-12 | $12.20M 10-Q · filed 2024-11-12 | $16.29M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-12 | $7.95M 10-Q · filed 2024-08-12 | $12.04M derived: sum of 3 quarters · filed 2024-08-12 | $15.59M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $4.46M 10-Q · filed 2024-05-08 | $8.54M derived: sum of 2 quarters · filed 2024-05-08 | $12.09M derived: sum of 3 quarters · filed 2024-05-08 | $15.96M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $7.64M derived: sum of 2 quarters · filed 2024-03-13 | $11.51M derived: sum of 3 quarters · filed 2024-03-13 | $14.91M 10-K · filed 2024-03-13 |
| 2022-09-30 | $3.55M 10-Q · filed 2023-11-06 | $7.42M derived: sum of 2 quarters · filed 2023-11-06 | $10.82M 10-Q · filed 2023-11-06 | $14.04M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $3.87M 10-Q · filed 2023-08-14 | $7.27M 10-Q · filed 2023-08-14 | $10.49M derived: sum of 3 quarters · filed 2023-08-14 | $13.86M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $3.40M 10-Q · filed 2023-05-11 | $6.62M derived: sum of 2 quarters · filed 2023-05-11 | $9.99M derived: sum of 3 quarters · filed 2023-05-11 | $10.52M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $6.59M derived: sum of 2 quarters · filed 2023-03-17 | $7.12M derived: sum of 3 quarters · filed 2023-03-17 | $7.73M 10-K · filed 2023-03-17 |
| 2021-09-30 | $3.37M 10-Q · filed 2022-11-10 | $3.90M derived: sum of 2 quarters · filed 2022-11-10 | $4.51M 10-Q · filed 2022-11-10 | $5.28M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $528.64K 10-Q · filed 2022-08-08 | $1.14M 10-Q · filed 2022-08-08 | $1.91M derived: sum of 3 quarters · filed 2022-08-08 | $3.46M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $613.98K 10-Q · filed 2022-05-12 | $1.38M derived: sum of 2 quarters · filed 2022-05-12 | $2.93M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $768.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $2.31M derived: sum of 2 quarters · filed 2022-03-21 | $3.60M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $1.55M 10-Q · filed 2021-11-15 | $2.83M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |